A Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Single and Multiple Doses of AL002 in Healthy Participants and in Participants With Mild to Moderate Alzheimer's Disease
Latest Information Update: 27 May 2022
At a glance
- Drugs AL-002 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; First in man
- Acronyms INVOKE
- Sponsors Alector
Most Recent Events
- 26 Apr 2022 Results presented at the 74th Annual Meeting of the American Academy of Neurology 2022
- 30 Jul 2021 Results of single ascending dose (SAD) portion of the study of INVOKE trial, presented at the Alzheimer's Association International Conference 2021.
- 07 Dec 2020 Status changed from active, no longer recruiting to completed.